The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study-Reference-Cited by-同舟云学术

The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study

Published:2017-01 Issue:13 Volume:12 Page:1614-1622
ISSN:1774-024X
Container-title:EuroIntervention
language:
Short-container-title:EuroIntervention

Author:

Varenne Olivier,Cuisset Thomas,Chaïb Aurès,Morice Marie-Claude,Sabaté Manel,Koh Tian-Hai,Durand-Zaleski Isabelle,Hanon Olivier,Bogaerts Kris,Sinnaeve Peter

Publisher

Europa Digital & Publishing

Subject

Cardiology and Cardiovascular Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platinum chromium everolimus-eluting stents for the treatment of (complex) coronary artery disease; from SYNERGY™ to the MEGATRON™;Expert Review of Medical Devices;2024-05-13

2. 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y₁₂ Receptor Inhibitor Monotherapy Using a Bioabsorbable Polymer Sirolimus-Eluting Stent;Circulation Journal;2020-12-25

3. Cancer treatment resumption in patients with new-generation drug-eluting stents;Coronary Artery Disease;2020-11-13

4. Two‐year outcomes after percutaneous coronary intervention with drug‐eluting stents or bare‐metal stents in elderly patients with coronary artery disease;Catheterization and Cardiovascular Interventions;2020-08-06

5. Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial;Value in Health;2019-12